Binding Site Expands Monoclonal Antibody Product Offerings
Availability of these products will enhance the needs of biopharmaceutical, clinical, and life science researchers, along with IVD manufacturer
San Diego, CA — Binding Site’s Immunologicals Group is pleased announce that it has just completed a major expansion to their monoclonal antibody product offerings. In addition to the established conjugated and unconjugated versions of the IgG4 Clone-HP6025 and the CD23 Clone BU-3438, Binding Site has recently introduced a number of new monolclonal antibodies focused on infectious diseases, including CMV, Hepatitis (A, B, C, and D), Herpes, HIV, Rubella, and Toxoplasma. Availability of these products will definitely enhance the needs of biopharmaceutical, clinical, and life science researchers, along with IVD manufacturers.
All of these antibodies exhibit outstanding degrees of specificity, while demonstrating high levels of purity, extended shelf-life stability claims, and lot-to-lot consistencies. The infectious disease monoclonal antibodies are all available in a standard-sized 1.0mg fill format, while the rest come in a 0.2mg fill format. Bulk packaging and customer-specific packaging options are for all available as well.
Binding Site’s Immunologicals Group serves the in-vitro diagnostic (IVD) manufacturing and clinical/life-science research markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 6730 Mesa Ridge Road, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: info@thebindingsite.com. Please visit our website at www.immunologicals.com.